JIR
HRTX icon

James Investment Research’s Heron Therapeutics HRTX Stock Holding History

James Investment Research’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,535
Closed -$49K – 845
2018
Q3 		$49K Hold
1,535
– – ﹤0.01% 684
2018
Q2 		$60K Hold
1,535
– – ﹤0.01% 662
2018
Q1 		$42K Buy
+1,535
New +$34.8K ﹤0.01% 685

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

James Investment Research's HRTX Position: Q4 2018 in Review

James Investment Research sold out of Heron Therapeutics (HRTX) in Q4 2018, closing a stake of 1,535 shares — an estimated $49K sold.

James Investment Research first reported a position in HRTX in Q1 2018 and held it in 3 quarters. The position peaked at $60K in Q2 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2018.

  • James Investment Research reported no remaining Heron Therapeutics position as of Q4 2018 after selling out during the quarter.
  • James Investment Research sold 1,535 Heron Therapeutics shares in Q4 2018, an estimated $49K.
  • James Investment Research first reported a position in Heron Therapeutics in Q1 2018 and held it in 3 quarters.
  • James Investment Research's Heron Therapeutics position peaked at $60K in Q2 2018.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2018.

Based on James Investment Research's 13F filing for Q4 2018, filed 22 Jan 2019.